Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidate

Orasis Pharmaceuticals announced the completion of its NEAR-1 and NEAR-2 phase 3 clinical studies.

“Orasis is committed to reshaping vision possibilities by developing a presbyopia eye drop with the patient in mind,” said Elad Kedar, Chief Executive Officer of Orasis. “Completion of this clinical trial milestone is exciting because it puts Orasis in position to be next in market. We look forward to sharing topline results in the coming months and advancing CSF-1 toward commercialization.”

The multicenter, double-masked, parallel-group clinical trials enrolled more than 600 participants in the US to evaluate the efficacy and safety of CSF-1, Orasis’ eye drop candidate.